P300 reduction and prolongation with illness duration in schizophrenia

被引:99
|
作者
Mathalon, DH
Ford, JM
Rosenbloom, M
Pfefferbaum, A
机构
[1] SRI Int, Neuropsychiat Program, Ctr Hlth Sci, Menlo Pk, CA 94025 USA
[2] Vet Affairs Palo Alto Hlth Care Syst, Psychiat Serv, Palo Alto, CA USA
[3] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA
关键词
P300; schizophrenia; onset; duration; age; neurodegeneration;
D O I
10.1016/S0006-3223(99)00151-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: The P300 component of the auditory event-related potential (ERP) is both reduced in amplitude and delayed in schizophrenia. P300 is prolonged and, less consistently, reduced with normal aging. Additional latency delays are observed in neurodegenerative disorders. We asked whether P300 is reduced and delayed with longer illness duration in schizophrenia, consistent with a neurodegenerative process. Methods: P300 amplitude and latency were recorded to infrequent auditory target stimuli from 35 men with schizophrenia (DSM-III-R) and 26 control men. Effects of current age, age of onset, and duration of illness on P300 were assessed using regression analysis. Results: P300 amplitude showed no age-related decrease in either group; however, among schizophrenic participants, P300 amplitude correlated positively with onset age and negatively with illness duration. P300 latency correlated positively with age in schizophrenic participants and also tended to increase with age in controls. Slopes of the latency-age relationships were significantly greater in schizophrenic participants than in control participants. Latency also correlated positively with illness duration but showed no relationship to onset age. Conclusions: P300 amplitude and latency are reduced and delayed with longer illness duration in schizophrenia, consistent with a progressive pathophysiological process. Reduced P300 amplitude may also be a marker of an early onset variant of schizophrenia. (C) 2000 Society of Biological Psychiatry.
引用
收藏
页码:413 / 427
页数:15
相关论文
共 50 条
  • [21] Auditory and visual P300 in schizophrenia
    Vohs, JL
    Bodkins, M
    Bismark, A
    O'Donnell, BF
    Shekhar, A
    Hetrick, WP
    PSYCHOPHYSIOLOGY, 2004, 41 : S34 - S34
  • [22] Schizophrenia: The broken P300 and beyond
    Ford, JM
    PSYCHOPHYSIOLOGY, 1999, 36 (06) : 667 - 682
  • [23] P300 - A BIOLOGICAL MARKER OF SCHIZOPHRENIA
    DUNCAN, CC
    DARRELL, GK
    PSYCHOPHYSIOLOGY, 1987, 24 (05) : 587 - 587
  • [24] P300 and symptom improvement in schizophrenia
    Jürgen Gallinat
    Michael Riedel
    Georg Juckel
    Safet Sokullu
    Thomas Frodl
    Renata Moukhtieva
    Paraskevi Mavrogiorgou
    Sonja Nisslé
    Norbert Müller
    Heidi Danker-Hopfe
    Ulrich Hegerl
    Psychopharmacology, 2001, 158 : 55 - 65
  • [25] Corpus callosum and P300 in schizophrenia
    Frodl, T
    Meisenzahl, EM
    Müller, D
    Greiner, J
    Juckel, G
    Leinsinger, G
    Hahn, H
    Möller, HJ
    Hegerl, U
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 107 - 119
  • [26] Is the P300 wave an endophenotype for schizophrenia?
    Bramon, E
    McDonald, C
    Croft, R
    Sham, P
    Frangou, S
    Murray, R
    EUROPEAN PSYCHIATRY, 2005, 20 : S45 - S45
  • [27] Bioelectric modeling of the P300 in schizophrenia
    Potts, GF
    Weinstein, DM
    O'Donnell, BF
    Shenton, ME
    Johnson, CR
    McCarley, RW
    BIOLOGICAL PSYCHIATRY, 1998, 43 : 119S - 119S
  • [28] PROGRESSIVE REDUCTION OF VISUAL P300 AMPLITUDE IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA
    McCarley, Robert
    Oribe, Naoya
    Hirano, Yoji
    del Re, Elisabetta C.
    Spencer, Kevin
    Niznikiewicz, Margaret
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S346 - S346
  • [29] ADDITIONAL REDUCTION OF P300 AMPLITUDE IN PATIENTS WITH A DUAL DIAGNOSIS OF SCHIZOPHRENIA AND ALCOHOLISM
    FORD, JM
    ISAACKS, BG
    JACKSON, D
    ROSENBLOOM, MJ
    PFEFFERBAUM, A
    SCHIZOPHRENIA RESEARCH, 1995, 15 (1-2) : 175 - 175
  • [30] Progressive Reduction of Visual P300 Amplitude in Patients with First Episode Schizophrenia
    McCarley, Robert
    Oribe, Naoya
    Hirano, Yoji
    Kanba, Shigenobu
    del Re, Elisabetta
    Seidman, Larry J.
    Mesholam-Gately, Raquelle
    Shenton, Martha
    Goldstein, Jill M.
    Spencer, Kevin M.
    Niznikiewicz, Margaret
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S447 - S447